• Our review reinforces the need for standardized outcome measures, larger studies of better quality and adequate reporting of future studies.
Acne vulgaris is a common inflammatory skin condition characterized by the formation of comedones, papules and pustules, and in severe cases nodules, deep pustules and cysts. 1, 2 Acne often leads to scarring, which is extremely difficult to treat. 3, 4 Acne can produce significant psychological and social problems, including lower self-esteem, anxiety, depression and low mood. [5] [6] [7] Current treatment options may be limited in effectiveness or acceptability owing to adverse effects, poor tolerability and inconvenience. 2, 8, 9 They are often complex for a person to use, time-consuming, can be costly and result in poor adherence. 10 Most oral and topical treatments are less effective than oral isotretinoin, but the latter has significant adverse effects. 2, 8, 9 Increasing concern has emerged as a result of the rise in antibiotic-resistant bacteria. 2 The question of safety and effectiveness of physical therapies, including light-based treatments, for acne is listed among the top research priorities. 8, 11 Light therapies utilize light with different properties (wavelength, intensity, coherent or incoherent light) with the aim of achieving a beneficial result. 12, 13 The exact mechanisms of action are still not fully understood, but three components are considered crucial: light, photosensitizers (i.e. molecules that absorb and are then activated by light) and oxidative stress resulting from their activation. [13] [14] [15] Photosensitizers can be produced endogenously or applied exogenously. 14 Propionibacterium acnes produces endogenous porphyrins, which absorb light to form a highly reactive singlet oxygen. 13 Photodynamic therapy (PDT) uses exogenous lightactivating topical products, consisting of various porphyrin precursors, most commonly 5-aminolaevulinic acid (ALA) and its methyl ester methyl-aminolaevulinate (MAL), which are absorbed into the skin. 16 Probable biological consequences of oxidative stress include damaging bacteria and sebaceous glands, together with reduction of follicular obstruction and hyperkeratosis. 13, 15 Possible interference with the immunological response, not necessarily mediated by photosensitizers, are also believed to be important. 15 The evidence regarding the efficacy of light-based treatments is not robust, which prevents recommendations for treatment, 2, 8, 17 and there is uncertainty and controversy. 9, 18 This article is a summary of a Cochrane review evaluating the effects of light-based interventions for acne vulgaris. 19 
Methods
We followed a previously published protocol for this review. 20 
Selection criteria
We included studies with participants diagnosed with acne vulgaris of any severity defined by any classification system.
We searched not only for any therapy based on the healing properties of light for the treatment of acne vulgaris, including laser-based treatments, but also accepted therapies that combined light with other treatments to boost the effect of the light. We included randomized controlled trials (RCTs) of different designs but excluded crossover trials. We included studies regardless of language or publication status.
Outcome measures
Primary outcomes included the following: (i) participant's global assessment of improvement, recorded using a Likert or Likert-type scale, or other scales; (ii) investigator-assessed change in lesion count [the change or percentage change from baseline in the number of inflamed lesions (ILs; papules, pustules or both), noninflamed lesions (NILs; blackheads, whiteheads or both), or nodules and cysts (for nodulocystic acne only)] -if individual lesion counts were not available, then the change or percentage change from baseline in the number of ILs and NILs, or combined count of all lesion types were assessed; (iii) investigator-assessed severe adverse effects -if blistering or scarring of the skin followed treatment with light therapy, we aimed to report on the severity of the adverse effect and whether it resolved in the short term or was permanent. Secondary outcomes included (i) investigator-assessed change in acne severity; (ii) investigator's global assessment of improvement; and (iii) changes in quality of life. We also recorded all other adverse events.
We considered short-term (2-4 weeks after final treatment), medium-term (5-8 weeks after final treatment) and long-term (> 8 weeks after final treatment) follow-up periods.
Search methods
Our searches up to September 2015 included the following databases: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and LILACS. We searched ISI Web of Science and Dissertation Abstracts International (from inception). We also searched five trials registers and grey literature sources. Two review authors independently assessed titles and abstracts. We resolved differences of opinion by discussion with the review team.
Data extraction and risk of bias assessment
Two review authors independently extracted data and used Cochrane's tool to assess independently the risk of bias of each included study. 21 We resolved differences of opinion by discussion with the review team. We contacted the corresponding researchers for clarification or additional data when necessary.
Statistical analyses and data synthesis
We expressed the results as risk ratio (RR) and 95% confidence intervals (CI) for dichotomous outcomes. When the relative risk was unreliable owing to the lack of events occurring in control groups or body sites, we provided event rates instead of RR and calculated risk differences with 95% CI. We used only mean differences (MD) where appropriate. 22 We expressed the results as 'number needed to treat' for an additional beneficial (NNTB) or harmful outcome for dichotomous outcomes where appropriate. For studies with acceptable levels of clinical and methodological heterogeneity, we performed a meta-analysis to calculate a weighted treatment effect across trials, using a random-effects model, 22, 23 or narratively synthesized the results. 24 We used the Grading of Recommendations Assessment, Development and Evaluation Working Group (GRADE) approach to assess the quality of evidence and created 'summary of findings' tables using GRADEpro Guideline Development Tool. 24, 25 For full details of methods (including search strategies), all studies and interventions, see the Cochrane review and Tables S1-S4 (see Supporting Information). 19 
Results
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) study flow diagram summarizes the results of our incorporated searches and reasons for exclusion (Fig. 1) . We included 71 studies, with a total of 4211 included participants (median sample size 31), of which 40 were studies of light therapies, excluding comparisons with PDT and randomized a total of 2485 participants, and 31 were studies of PDT (including comparisons with light therapies), which included a total of 1726 participants. Most studies were of single-centre design and did not report on funding sources, or were sponsored by industry if multicentre. Most studies included participants with a mean age of 20-30 years, of both sexes, with mild-to-moderate acne. Many studies did not report on Fitzpatrick skin type (FPTs) and a great proportion of studies that did included up to three FPTs. 26 The number of light sessions of the interventions varied from 1 to 112, with 2-4 sessions being the most common. Frequency of application varied from twice daily to once monthly. As presented in Figure 2 , selection bias was unclear for the majority of studies, with about half of studies describing adequate methods of random sequence generation and fewer than a third of studies describing adequate allocation concealment methods. Performance bias was also unclear in more than half of studies, high in about a quarter and unclear in the remaining studies. Out of 26 studies that included participant-assessed outcomes, detection bias was low in only two studies, high in 10 studies and unclear in the remaining studies. Detection bias was low in over half of studies for investigator-assessed outcomes and unclear in most of the rest. Attrition bias was low in over half of studies, high in about a quarter and unclear in a few studies only. Reporting bias was similar. Other risk of bias was low in about a third of studies. Two-thirds of studies had unclear risk because possible conflicts of interest or sponsorship, or both, were not declared; they were industry-sponsored; or they reported some sort of conflict of interest, and a few studies had a high risk for other reasons, such as baseline imbalances and concomitant treatment.
Summary of findings for our primary outcomes are presented in Table 1 , together with an overview of 10 studies which included reports of investigator-assessed severe adverse effects. In the narrative summary that follows we highlight the interventions from studies with a total sample size of 31 (median) or more which included the first two primary outcomes and evaluation time points of interest for our review.
Yellow light vs. placebo or no treatment
Our analyses confirmed results reported from a split-face trial (n = 40), which compared one or two light treatments with no treatment, 27 and found no significant differences between the treated and untreated sides of the face at 12 weeks in changes in ILs [MD À2Á00 (95% CI À6Á60 to 2Á60) for papules; MD 1Á00 (95% CI À0Á66 to 2Á66) for pustules]; NILs (MD 1Á30, 95% CI À8Á00 to 10Á60) and cysts (MD 0Á00, 95% CI À0Á76 to 0Á76). However, a parallel-group trial (n = 41), found significantly greater improvement from baseline in IL and total lesion counts in the laser-treated group than in the placebo group at 12 weeks, but owing to lack of data we were unable to confirm the results nor combine the results in a meta-analysis. 28 
Infrared light vs. no treatment
Our analyses confirmed results reported from a split-face trial (n = 48), 29 and found no significant differences in means between 1450-nm laser-treated and untreated face sides 8 weeks after final treatment in changes in ILs [MD À0Á54 (95% CI À3Á71 to 2Á63) for papules; MD À0Á73 (95% CI À4Á37 to 2Á91) for pustules] and NILs [MD À2Á92 (95% CI À8Á13 to 2Á29) for open comedones; MD À6Á95 (95% CI À23Á07 to 9Á17) for closed comedones]. The difference in means for changes in cysts was significant, favouring infrared light (MD À0Á43, 95% CI À0Á80 to À0Á06). Another split-face trial of neodymium-doped yttrium aluminium garnet laser treatment (n = 38) 30 found similar reduction in ILs at 1 and 12 months on both treated and untreated face sides, whereas a smaller split-face study of four treatments with fractional erbium glass laser (n = 24) found differences in reduction in ILs and NILs to be significant. 31 We were unable to confirm the results of the latter two trials owing to lack of data.
30,31
Blue-red light vs. placebo
Our analyses confirmed part of the results reported from a parallel-group study with 84 treatments (n = 55 in the relevant study arms), 32 favouring blue-red light in participants' global assessment of improvement (RR 3Á21, 95% CI 1Á70-6Á09; NNTB 2, 95% CI 1-3), but the final assessment was done at final treatment only. The authors reported significant differences in mean percentage improvements in ILs (MD 50Á3, 95% CI 40Á1-60Á5) and in NILs (MD 66Á5, 95% CI 56Á0-77Á0) at final treatment. Blue-red light was reported to be superior in participant's global assessment of improvement, as well as reduction and percentage reduction in ILs and NILs at 8 weeks after final treatment in one more parallel group study with 56 treatments (n = 35). 33 However, we were unable to obtain original data and confirm the results.
Light vs. topical treatments
One parallel-group trial compared eight treatments of blue light (n = 60) with 5% benzoyl peroxide (BPO). 34 Our analyses confirmed a similar decrease in means of NILs (MD 9Á49, 95% CI À10Á84 to 29Á82) between the blue light and BPO group; however, owing to lack of data, we were unable to confirm the MD in reductions in ILs. 34 Our analyses confirmed part of the results reported from a parallel-group study comparing 84 treatments of blue-red light with BPO (n = 55 in the relevant study arms), 32 showing a nonsignificant difference in participant's global assessment of improvement (RR 1Á13, 95% CI 0Á89-1Á42), but the final assessment was done at last treatment only. The authors reported the differences in mean percentage improvements in ILs (MD 17Á6, 95% CI 7Á5-27Á6) and in NILs (MD 0Á9, 95% CI À9Á4 to 11Á3) at final treatment. An additional split-face study compared a combination of BPO and three sessions of 530-750-nm light with BPO alone (n = 30) 35 and found no significant difference between light-treated and untreated sides of the face for changes in mean papule and pustule counts. We were unable to obtain original data to confirm the findings. A parallel group trial compared clindamycin 1%-benzoyl peroxide 5% hydrating gel (C/BPO) alone applied daily over 4 weeks, with C/BPO in combination with two 585-nm pulsed dye laser (PDL) treatments (n = 89). 36 Changes in IL counts and in total lesion counts were reported in graphical format, and we were unable to confirm results of no significant difference between the two groups at 2 weeks after final treatment.
Methyl-aminolaevulinate photodynamic therapy vs. red light alone
Using a random-effects model, we combined results of three parallel-group studies (n = 360 in the relevant study arms) comparing four sessions of red light plus 80 mg g À1 MAL with placebo cream and red light. [37] [38] [39] At 6 weeks after the last treatment MAL-PDT was not superior to red light alone for changes and percentage changes in ILs nor NILs (see Table 2 , where we rated the evidence as of moderate quality for these outcomes). One of the above-mentioned studies had an additional arm (n = 50) treated with 40 mg g À1 MAL-PDT. 37 Our analyses showed this treatment was not superior to placebo cream plus red light in change in ILs (MD À3Á00, 95% CI À7Á76 to 1Á76), in percentage change in ILs (MD À7Á90, 95% CI À22Á33 to 6Á53) and in change in NILs (MD À7Á50, 95% CI À16Á07 to 1Á07), whereas there was a borderline superiority in percentage change in NILs (MD À25Á80, 95% CI À51Á69 to 0Á09). A smaller split-back trial compared two sessions of red light plus 80 mg g À1 MAL with placebo cream and red light (n = 20). 40 Our analyses showed that at 4 weeks after final treatment MAL-PDT was not superior in changing the IL count (MD 0Á20, CI 95% À1Á24 to 1Á64) nor the NIL count (MD À0Á45, CI 95% À2Á95 to 2Á05). A split-face trial compared two sessions of 635-nm light plus 160 mg g À1 MAL with placebo cream and light (n = 30). 41 We calculated that MAL-PDT was not superior to placebo cream plus light in change in ILs at 4 weeks (MD À2Á60, 95% CI À6Á45 to 1Á25) nor at 10 weeks (MD À2Á50, 95% CI À6Á59 to 1Á59). However, it was superior in percentage change in ILs at 4 weeks (MD À23Á90, 95% CI À39Á04 to À8Á76) and at 10 weeks (MD À19Á10, 95% CI À37Á63 to À0Á57).
Methyl-aminolaevulinate photodynamic therapy vs. placebo or no treatment
Authors of a parallel-group study of two treatments of 630 nm plus 160 mg g À1 MAL (n = 36) reported a significantly greater median reduction in ILs in the treatment group at 8 weeks and 12 weeks, but a nonsignificant difference in median change in NILs at 12 weeks. 42 Results for participant's global assessment of improvement were only reported in graphical format. Owing to lack of data, we were unable to perform analyses and confirm results.
Methyl-aminolaevulinate photodynamic therapy: other
A parallel-group trial (n = 44) compared four treatments of 80 mg g À1 MAL with or without occlusion followed by different red light intensity exposure; participants were randomized in four groups with 25 J cm À ² or 37 J cm À ² and with or without occlusion. 43 The authors reported no statistically significant difference in mean reduction of ILs nor NILs between face sides at 12 weeks after final treatment, but owing to lack of data we were unable to perform analyses and confirm the results. Two arms of the previously listed parallel-group trial (n = 98 in the relevant trial arms) included 80 mg g À1 MAL-
PDT arm and 40 mg g À1 MAL-PDT arm (four treatments). 37 Our analyses showed that at 6 weeks after final treatment 80 mg g À1 MAL-PDT was not superior to 40 mg g À1 MAL- Three studies on methyl aminolaevulinate (MAL)-PDT (one of which is presented in Table 2 ); the second was a split-face, within-parallel-group trial, including one report on 37 J cm PDT studies: one split-face trial included one report [1/44 (2%)] on the sides with pulsed dye laser used for activation and no reports on the untreated sides. One split-back, within-parallel-group included one report [1/11 (9%)] in the single-treatment group on back sites with 550-700-nm light used for activation, and no reports in the multiple treatment groups on the ALA-PDT, nor ALA alone, light alone or untreated back sites in any of the groups. One parallel-group trial included one report in the arm that used a combination of IPL of 580-980 nm and bipolar radiofrequency energies for activation, and no reports in the arms that used 517-nm light or IPL-alone (600-850 nm) for activation; the number of participants per group unclear. One parallel-group trial included one report in the arm which used 20% ALA [1/45 (2%)] and no reports (0%) in arms with 5%, 10% or 15% ALA activated by 633-nm light. We did not downgrade because of inconsistency. There was some clinical heterogeneity across studies to take into account: in one study only participants with severe acne were included, in the other two studies participants with both moderate and severe acne were included (< 20% of the included participants had severe acne in those trials).
e
The three studies included 53, 53 and 52 participants in the control group and 100, 54 and 48 participants in the intervention group, respectively. We did not downgrade because of imprecision, but small numbers of participants need to be considered by the readers. PDT in change in ILs (MD 2Á20, 95% CI À2Á57 to 6Á97), in percentage change in ILs (MD 3Á10, 95% CI À11Á8 to 17Á38), in change in NILs (MD 0Á6, CI 95% À6Á36 to 7Á56) or in percentage change in NILs (MD À1Á7, 95% CI À20Á67 to 17Á27).
5-Aminolaevulinic acid photodynamic therapy vs. light alone
One parallel-group trial (n = 266) compared four interventions: 44 For participant's global assessment of improvement, the difference between ALA 1000 s and vehicle 1000 s groups was nonsignificant (RR 0Á94, 95% CI 0Á72-1Á22); and it was nonsignificant between ALA 500 s and vehicle 500 s groups (RR 0Á81, 95% CI 0Á63-1Á03). Using a random-effects model, the difference remained nonsignificant when we combined results for the 1000 s and 500 s subgroups (RR 0Á87, 95% CI 0Á72-1Á04). Statistical tests to determine whether there were significant differences between the groups for investigator-assessed changes in ILs at 3 weeks after final treatment could not be performed owing to the study authors' use of median changes (see Table 3 , where we rated the evidence as low and very low quality for this comparison).
Our analyses also showed that for participant's global assessment of improvement the difference between vehicle 1000 s blue light and vehicle 500 s blue light groups was nonsignificant (RR 0Á86, 95% CI 0Á69-1Á09), and it was nonsignificant between the arms with 20% ALA plus 500 s blue light and 20% ALA plus 1000 s blue light (RR 1Á00, 95% CI 0Á76-1Á33).
One parallel-group trial (n = 41) compared four treatments of 10% ALA plus intense pulsed light (IPL) with placebo cream plus IPL. 45 Our analyses confirmed that ALA-PDT was superior to light alone in percentage decreases in ILs (MD 13Á80, 95% CI 1Á34-26Á26) and in percentage changes in NILs (MD 24Á10, 95% CI 4Á65-43Á55).
5-Aminolaevulinic acid photodynamic therapy vs. no treatment
One split-face trial (n = 44) compared three sessions of 20% ALA plus PDL with untreated control. 46 Our analyses confirmed a transient statistically significant decrease from baseline in change in ILs (papules) on treated sides when compared with untreated sides 4 weeks after final treatment (MD À4Á50, 95% CI À8Á28 to À0Á72). We found no significant differences in means between treated and untreated sides of the face for investigator-assessed change in pustules (MD À0Á60, 95% CI À5Á09 to 3Á89), in NILs [MD À0Á37 (95% CI À7Á76 to 7Á02) for open comedones; MD À3Á90 (95% CI À12Á05 to 4Á25) for closed comedones] and for cysts (MD 0Á03, 95% CI À0Á53 to 0Á59). Our analyses also confirmed no significant differences in means between treated and untreated sides of the face 10 weeks after final treatment in investigatorassessed change in ILs [MD À0Á82 (95% CI À6Á03 to 4Á39) for papules; MD À0Á10 (95% CI À5Á29 to 5Á09) for pustules]; in NILs (open comedones) [MD 2Á00 (95% CI À7Á51 to 11Á51) for open comedones; MD À2Á90 (95% CI À10Á78 to 4Á98) for closed comedones] and cysts (MD 0Á14, 95% CI À0Á66 to 0Á94).
5-Aminolaevulinic acid photodynamic therapy: other
A parallel group trial compared four red light ALA-PDT treatments with different ALA concentrations: 20%, 15%, 10% and 5% (n = 180). 47 The study authors reported that at 24 weeks for ILs 'a significant statistical difference was found in multiple comparisons between 5%, 10%, 15% and 20% ALA (P < 0Á05), except between 15% and 20% ALA (P = 0Á148)' and for NILs 'a significant statistical difference was found in multiple comparisons between 5%, 10%, 15% and 20% ALA (P < 0Á05), except for 5% ALA vs. control (P = 1Á734) and 15% vs. 20% ALA (P = 0Á327)'. Results were presented in graph format only, which prevented further analyses. Our analyses for participants' global assessment of improvement showed that 20% ALA was not superior to 15% ALA (RR 1Á05, 95% CI 0Á96-1Á15). However, 20% ALA was more effective than 10% ALA (RR 1Á22, 95% CI 1Á05-1Á42; NNTB 6, 95% CI 3-19) and more effective than 5% ALA (RR 1Á47, 95% CI 1Á19-1Á81; NNTB 4, 95% CI 2-6).
Gold microparticle photodynamic therapy vs. other comparators
One parallel-group trial compared three sessions of gold microparticle suspension plus light (details not given) with vehicle plus light (details not given) control (n = 51). 48 Gold microparticle PDT was reported to be superior in reducing the mean percentage change in IL count at 6, 10 and 14 weeks after final treatment. Owing to lack of data, we were unable to confirm these findings.
Discussion
We included 71 studies with a total of 4211 participants. Most studies had small sample sizes, were single centre and included participants with a mean age of between 20 and 30 years, of both sexes, with mild-to-moderate acne. Two to four light sessions were the most common. The overall quality of evidence was very low. We identified the greatest body of moderate-quality evidence for the comparison of MAL-PDT and red light only, which does not support the use of MAL-PDT as a standard therapy for people with moderate-to-severe acne. The use of 20% ALA-PDT activated by blue light as a standard therapy for people with moderate-to-severe acne was not supported by the evidence (low and very low quality) as this treatment did not show superior effectiveness in comparison with blue light alone. However, the overall evidence suggests that using lower ALA doses (15% and 10%), together with light modalities other than blue light, may be of benefit. This is because several studies found that 20% ALA had more adverse effects (including blistering), whereas individual studies also found that, for example, 20% ALA activated by red light was not more effective than 15% ALA activated by red light, and 10% ALA activated by IPL was more effective than IPL alone. Although the evidence was not conclusive and we were unable to combine it quantitatively, studies with a larger number of participants and of high overall risk of bias showed that infrared light was not more effective than placebo or no treatment and had more side-effects, including blistering. Several studies compared yellow light with placebo or no treatment, infrared light with no treatment, gold microparticle suspension with vehicle and C/BPO combined with pulsed dye laser to C/BPO alone. None of these showed any clinically significant effects. A few smaller studies reported blue-red light to be superior to placebo, and blue light to have similar effects as BPO. The major strengths of this review include a comprehensive search for all eligible studies, irrespective of language or publication status, and rigorous methods expected by the Cochrane Collaboration in data extraction, analysis and synthesis, as well as assessment of risk of bias and the quality of evidence using the GRADE approach. A variety of interventions (different photosensitizers, wavelengths, fluencies, light doses, numbers of sessions, frequency of application), patient and comparison groups have been included in this review, but there are still a lot of combining possibilities that were not performed in the studies we included. Furthermore, lack of data on some of the above characteristics limits our ability to evaluate fully the impact on the therapeutic outcome of acne light, laser and PDT treatments. There were only a few studies using the conventional treatments documented in guidelines as a control. 2, 8 Important factors that should be considered in the context of limited generalizability are participants' sex and age, different FPTs and acne severity. 26, [49] [50] [51] High and unclear overall risk of bias in most studies, together with poor reporting in general, may have introduced bias in our assessment of some studies, as well as our failure to obtain the additional data we needed to clarify ambiguities resulting from such poor reporting. Our findings are in line with previous reviews regarding the general direction of evidence for most light therapies. 12, 17, 52 We screened out non-RCTs and found the evidence to still be inconclusive, which is somewhat different from previous reviews. 53, 54 We included several new studies with larger samples mostly identified through grey literature searches, and so our conclusions regarding the effectiveness of PDT are different to those of reviews on PDT-only studies covering published evidence. 12, 15, 17, 52, 55, 56 Despite our effort, publication bias may have still affected the results of our review. Our results reinforce the need for standardized outcome measures, larger studies of better quality and adequate reporting, raised by earlier Cochrane reviews on acne. [57] [58] [59] Owing to limited evidence, we are unable to draw firm conclusions from the results of this review to guide decisions in practice, especially considering the cost of light-based treatments. In particular, the lack of long-term outcomes was a major drawback because if a treatment does not give at least 3 months' benefit, it could arguably be considered a treatment failure. Furthermore, only a minority of studies included participant-assessed outcomes, although of primary interest in this review. Future research must take into account the methodological and reporting issues, as well as whether the following have implications for practice: the possible superior effectiveness of MAL-PDT in those with severe acne; the use of blue light, red light, blue-red light and green light alone; 15% ALA-PDT activated by red or blue-red light; as well as PDT modalities other than MAL-and ALA-PDT, compared with conventional treatments, placebo or no treatment. In summary, more robust, well-planned studies with greater sample sizes comparing the effectiveness of common acne treatments with light therapies would be welcomed together with adherence to the CONSORT guidelines. 60 
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